BPC-157 vs Naltrexone/Bupropion (Contrave)
Both are used for gut health. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| BPC-157 | Naltrexone/Bupropion (Contrave) | |
|---|---|---|
| Human evidence | ★★★☆☆ | ★★★★☆ |
| Legal status | Not Approved | FDA Approved |
| How it works | A 15-amino-acid fragment of a gastric protein. Two characterised pathways: (1) upregulates VEGFR2 (KDR) → PI3K/Akt → eNOS (NOS3), driving angiogenesis (new blood vessels to injured tissue); (2) a Src–Caveolin-1–eNOS route. It also… | Bupropion stimulates hypothalamic POMC neurons (dopamine/norepinephrine reuptake inhibition); naltrexone (opioid µ-receptor, OPRM1 antagonist) blocks POMC's auto-inhibition — together sustaining appetite/craving suppression. |
| In plain English | It tells injured tissue to grow a fresh blood supply (via the VEGFR2 switch), and blood flow is what healing runs on — so tendons, ligaments, gut lining and muscle appear to mend faster. The catch: almost all the evidence is in rats. Human… | Targets the brain's reward/craving circuit rather than gut fullness — useful for emotional or reward eating. Modest (~5–9%) loss. |
| Bottom line | The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. | Reasonable non-GLP-1 option, especially for craving-driven eating. |
| Availability | Not widely approved | Available over the counter |
Which is better for gut health?
Naltrexone/Bupropion (Contrave) has the stronger human-evidence rating (★★★★☆ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
Full breakdowns: BPC-157 · Naltrexone/Bupropion (Contrave).
Common questions
Is BPC-157 or Naltrexone/Bupropion (Contrave) better for gut health?
Naltrexone/Bupropion (Contrave) has the stronger human-evidence rating (★★★★☆ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
What's the difference between BPC-157 and Naltrexone/Bupropion (Contrave)?
BPC-157: The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. — Naltrexone/Bupropion (Contrave): Reasonable non-GLP-1 option, especially for craving-driven eating.